Back to search resultsSummaryRMgm-4405
|
||||||||
*RMgm-4405| Successful modification | The parasite was generated by the genetic modification |
| The mutant contains the following genetic modification(s) | Gene disruption |
| Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 29253313 |
| MR4 number | |
| top of page | |
| Parent parasite used to introduce the genetic modification | |
| Rodent Malaria Parasite | P. yoelii |
| Parent strain/line | P. y. yoelii 17XNL |
| Name parent line/clone | Not applicable |
| Other information parent line | |
| top of page | |
| The mutant parasite was generated by | |
| Name PI/Researcher | Steel RWJ, Kappe SHI |
| Name Group/Department | Center for Infectious Disease Research |
| Name Institute | formerly Seattle Biomedical Research Institute |
| City | Seattle |
| Country | USA |
| top of page | |
| Name of the mutant parasite | |
| RMgm number | RMgm-4405 |
| Principal name | Py s4/celtos(-) |
| Alternative name | |
| Standardized name | |
| Is the mutant parasite cloned after genetic modification | Yes |
| top of page | |
| Phenotype | |
| Asexual blood stage | Not different from wild type |
| Gametocyte/Gamete | Not different from wild type |
| Fertilization and ookinete | Normal gametocyte and ookinete production. Surprisingly PPy s4/celtos¯ parasites also established a low-level mosquito midgut infection. |
| Oocyst | Normal gametocyte and ookinete production. Surprisingly Py s4/celtos¯ parasites also established a low-level mosquito midgut infection. Whereas the number of oocysts per midgut stayed stable between days 7 – 11 for Py WT, oocyst numbers for Py s4/celtos¯ parasites declined throughout this period. The fraction of midguts infected with Py s4/celtos¯ declined markedly from day 7 - 11, by which time oocysts were only occasionally observed and these exhibited defects in sporulation compared to Py WT oocysts. Combined, the data suggest that Py S4/CelTOS has an important role during oocyst survival and/or sporogenesis in addition to the previously reported role in ookinete traversal of the midgut epithelium. |
| Sporozoite | No salivary gland sporozoites. |
| Liver stage | Not tested |
| Additional remarks phenotype | Mutant/mutation |
Disrupted: Mutant parasite with a disrupted gene| top of page | |||||||||||||||||||||||||
| Details of the target gene | |||||||||||||||||||||||||
| Gene Model of Rodent Parasite | PY17X_1434600 | ||||||||||||||||||||||||
| Gene Model P. falciparum ortholog | PF3D7_1216600 | ||||||||||||||||||||||||
| Gene product | cell traversal protein for ookinetes and sporozoites | ||||||||||||||||||||||||
| Gene product: Alternative name | CelTOS, S4 | ||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||
| Details of the genetic modification | |||||||||||||||||||||||||
| Inducable system used | No | ||||||||||||||||||||||||
| Additional remarks inducable system | |||||||||||||||||||||||||
| Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
| PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
| Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
| Plasmid/construct map | |||||||||||||||||||||||||
| Plasmid/construct sequence | |||||||||||||||||||||||||
| Restriction sites to linearize plasmid | |||||||||||||||||||||||||
| Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
| Additional remarks partial/complete disruption | |||||||||||||||||||||||||
| Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
| Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
| Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
| Selection (negative) procedure | No | ||||||||||||||||||||||||
| Additional remarks genetic modification | To generate Py s4/celtos¯, two DNA fragments containing approximately 800 bp of the 5′ UTR and 3′ UTR of Py S4/CelTOS were amplified from WT Py 17XNL genomic DNA and cloned into the pDEF vector (BEI Resources). | ||||||||||||||||||||||||
| Additional remarks selection procedure | |||||||||||||||||||||||||
|
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
| top of page | |||||||||||||||||||||||||